Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients
Launched by YONGTAO SUN · Nov 22, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a medication called low-dose esmolol might help prevent heart injury in elderly patients who are frail and undergoing non-cardiac surgery. The study aims to understand the connection between frailty—a state of increased vulnerability due to aging—and heart injury after surgery. Researchers will also identify factors that could predict heart injury in these patients before they have surgery.
To be eligible for this trial, participants must be at least 65 years old, have a certain level of frailty, and be scheduled for non-cardiac surgery. However, patients with certain heart conditions or who are taking specific heart medications will not be included. If you join the study, you will receive either the medication or a placebo (a non-active treatment) and help researchers learn more about how to protect heart health in older adults during surgery. Your participation could contribute to important findings that may benefit future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 65 years;
- • 2. ASA: ⅰ-ⅳ;
- • 3. Modified frailty index (mFI) ≥ 0.21;
- • 4. Patients undergoing non-cardiac surgery.
- Exclusion Criteria:
- • 1. Refuse to participate;
- • 2. Expected hospital stay \<3 days;
- • 3. Preoperative β-blocker therapy;
- • 4. History of myocardial infarction or coronary artery disease;
- • 5. Preoperative bradycardia (heart rate \[HR\] \< 50 bpm) or arrhythmia;
- • 6. Significant cardiac insufficiency (i.e., pulmonary artery pressure \>18 mm Hg, cardiac index ≤ 2.2 L/min/m 2);
- • 7. Severe valvular heart disease;
- • 8. Severe lung disease (e.g. asthma or chronic obstructive pulmonary disease);
- • 9. Patients with perioperative troponin elevation due to nonischemic causes (e.g., sepsis, pulmonary embolism, arrhythmia);
- • 10. The same patient can only be included once, regardless of whether the reason for the second operation is related to the first cause.
- • -
About Yongtao Sun
Yongtao Sun is a distinguished clinical trial sponsor recognized for advancing medical research through innovative study designs and rigorous methodologies. With a commitment to enhancing patient care and outcomes, Yongtao Sun leads initiatives across various therapeutic areas, collaborating with healthcare professionals and institutions to ensure the highest standards of ethical conduct and scientific integrity. The organization is dedicated to fostering a collaborative environment that accelerates the development of safe and effective therapies, ultimately contributing to the improvement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials